WHO vaccine-preventable diseases: monitoring system. 2014 global summary

Last updated 15-Jul-2014 (Data received as of 8-Jul-2014)
Next overall update Fall 2014
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 34'4001 Infant (under 12 months) mortality rate: 32
GDP / capita (US$): 34'3031 Child (under 5 years) mortality rate: 42

Population data in thousands3

  2013  2012  2011  2010  2009  2000  1990  1980 
Total population 60'990  60'885  60'729  60'509  60'220  56'986  56'832  56'221 
Births 560  563  565  567  566  523  555  673 
Surviving infants 558  561  564  565  564  521  551  663 
Pop. less than 5 years 2'859  2'851  2'845  2'846  2'843  2'629  2'768  3'573 
Pop. less than 15 years 8'573  8'552  8'525  8'495  8'457  8'162  9'358  12'496 
Female 15-49 years 13'629  13'774  13'893  13'981  14'021  13'864  14'281  13'585 

Number of reported case

(Click for retrospective incidence data for Italy)
Diphtheria 30 
Japanese encephalitis
Measles 376  5'189  372  351  1'457  5'223  27'452 
Mumps 322  726  530  769  37'669 
Pertussis 225  302  187  315  2'543  16'992  16'643 
Polio*
Rubella 85  84  47  106  2'605 
Rubella (CRS)
Tetanus (neonatal)
Tetanus (total) 64  58  57  62  98  123  176 
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV);"
"it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Italy)
Vaccine year result method % card seen                                                
BCG         
DTP1         
DTP3 2007  97       97  96  96  96  87  80 
HepB_BD         
HepB3 2007  97       97  96  96  96  94 
Hib3 2007  96       96  96  95  96  55 
JapEnc         
MCV 2006  90       90  90  91  90  74  43 
MCV2         
PCV1         
PCV3 2007  55      
Pol3 2007  97       97  96  96  96  97  98 
Rota1         
Rota_last         
Rubella1          90  90  91  90  74 
TT2plus         
PAB         
VAD1         
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: July 2015

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Italy)
BCG
DTP1 99  99  98  98  98  95  94 
DTP3 97  97  96  96  96  87  83 
HepB3 97  97  96  96  96  94 
HepB_BD
Hib3 96  96  96  95  96  55 
MCV 90  90  90  91  90  74  43 
MCV2
PCV3 55  55  55  55  55 
Pol3 97  97  96  96  96  97  98 
Rota_last

Number of districts in the country 21  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
 
   
/
|
|
\
Greater or equal to 90% 67
From 80 to 89% 0
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
33
 

Immunization Schedule (2013 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG Yes health workers at high risk
DTaP 3, 5-6, 11-13 months; 5-6, 11-18 years; Yes
DTaPHepIPV 3, 5-6, 11-13 months; Yes
DTaPHib 3, 5-6, 11-13 months; Yes
DTaPHibHepIPV 3, 5-6, 11-13 months; Yes
DTaPHibIPV 3, 5-6, 11-13 months; Yes
DTaPIPV 3, 5-6, 11-13 months; 5-6 years; Yes
HPV 12 years; +1-2, +6 months; Yes girls
HepA Yes recommended for persons with clinical, behavioral or occupational indications
HepAHepB Yes recommended for persons with clinical, behavioral or occupational indications
HepB 3, 5-6, 11-13 months; Yes also recommended for persons with clinical, behavioral or occupational indications
Hib 3, 5-6, 11-13 months; Yes
IPV 3, 5-6, 11-13 months; 5-6 years; Yes
Influenza >= 65 years; Yes and high risk groups
MMR 13-15 months, 5-6 years; Yes
MenC_conj 13-15 months; Yes
Pneumo_conj 3, 5-6, 11-13 months; Yes
Pneumo_ps Yes recommended for children and adults with clinical indications
TT 3, 5-6, 11-13 months; 5-6, 11-18 years; Yes and every 10 years
Td 11-18 years; Yes every 10 years
Tdap 11-18 years;
Varicella 13-15 months; 5-6 years; Yes

Immunizaton indicators

Indicator Expected answer 2013  2012  2011  2010  2009  2008  2007 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR   Yes  Yes  Yes  Yes    Yes 
What years does the MYP cover? number   2012-2014  2012-2014  2010-2012     
Nº of districts with microplans that include activities to raise immunization coverage number   16      21    21 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR   No  No  No       

System performance

Total Nº districts in country number   21  21  21  21  21   
Nº districts with DTP3 coverage >=80% number   14  14 
% of districts with DTP3 coverage >=80% From 0 to 100%   67  67   
Nº districts with measles (MCV1) coverage >=95% number          
% of districts with MCV1 coverage >=95% From 0 to 100%          

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND   No  Yes  No       
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR   Yes    Yes  Yes    Yes 

Finance

Estimated percentage of routine vaccines funded by Government From 0 to 100%   100  100  100  100     

Sources

Unless otherwise specified, data provided by Member States through WHO-UNICEF Joint Reporting Form and WHO Regional offices.
 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.